Atenolol-Once-daily Dosage by Dr A J Marshall (Bristol Royal Infirmary, Bristol) It is not many years since Sir Thomas Lewis advocated that all the patients who have a raised blood pressure should rest, keep their bowels lax with saline purgatives, not take tobacco, be allowed wine but no beer, and spend as much time as possible in the open air. He concluded that the regime could be more readily carried out at some soothing country spot or quiet seaside place (Lewis 1949) . Since this was accepted advice there have been two major developments in the treatment of hypertension. First there has been the discovery of effective drug therapy, and secondly the realization that even completely symptom-free patients with only moderate elevation of the blood pressure may benefit from that therapy. It is for people such as these that we would like to prescribe a normal life, apart that is from the need to take some tablets. Lewis's restrictive regime has been superseded but if drugs are used to lower blood pressure they too should ideally not interfere with normal life style. Many asymptomatic patients would consider it a poor bargain to exchange a statistical chance of a longer life for common enough side-effects of some hypotensive agentslifelong lethargy, impotence and the risk of falling down every time they stand up. The beta-blocking drugs rarely cause postural hypotension or mental slowing and these advantages, with a low incidence of interference with sexual activity, account for their popularity.
There is still conflicting evidence about the effective dose range and dose frequency of most of the beta-blocking drugs. Clearly the need to swallow several tablets several times a day is a considerable nuisance to many patients. There is no doubt that the only acceptable way to make recommendations about the size and frequency of dosage of any hypotensive agent is by means of well-organized, double-blind trials, designed specifically to look at dose range and frequency. This has been done with atenolol.
The trial was carried out in a blood pressure clinic where efforts were made to minimize the variability of blood pressure, which tends to interfere with the assessment of any hypotensive agent. Measurements of pressure and heart rate were made by the same observer, a well-trained and welcoming clinic nurse, at the same time of the day in three positions, lying, standing and postexercise. A random zero sphygmomanometer was used. The patients studied were previously un-treated and during the placebo run-in period they all maintained a supine blood pressure greater than 170/1 10 mmHg, the diastolic pressure being recorded at phase V. Sixteen patients, 10 men, 6 women (age range 32-69 years), completed the whole trial. The trial was double-blind, using three doses of atenolol, 50mg, 100 mg, and 200mg, twice a day, given in a randomized order according to a Latin square design. The placebo tablets were given during a four-week run-in period, and during the two-week wash-out periods, between doses. Observations were made at two-weekly intervals throughout. Table I shows some of the results from which it can be seen that there is usually no benefit from increasing the dose of atenolol above 50 mg twice a day, and this confirms other independent findings. Patients who achieved an adequate fall in blood pressure on twice-daily atenolol were then given once-daily placebo tablets for a month followed for a further month by once-daily atenolol. Blood pressures were measured 22-24 hours after the last dose. Comparing the blood pressure results from once to twice-daily treatment showed that the level of blood pressure achieved by both regimes was similar (151/94 once-daily; 150/91 twice-daily). There seems to be no benefit, therefore, in giving this drug twice a day compared to once-daily. It has been suggested that blood pressure fall with exercise may be inadequate when atenolol is given only once a day. Table 2 shows the exercise blood pressure figures in this group of patients and again they are nearly the same whether the dose was given once or twice a day. The heart rate was iden>tical. The ideal of a one tablet once a day treatment with beta blockade has now apparently been achieved.
During this trial an estimate was made of drug defaulting. The matching atenolol and placebo tablets were dispensed in containers on which the instructions for use were clearly marked. Twelve tablets in excess of the required number for each two-week treatment period were included and the patients were asked to return the container at each visit. Tablet counts were made at the end of the trial. One hundred and twelve analyses were made of 16 patients while they were taking atenolol and 58 while they were taking placebo. In only 66% of the analyses had 80% or more of the tablets been taken. There was no difference between placebo and atenolol compliance, which suggests that side effects due to treatment were not so severe as to stop patients taking the active drug. There was some improvement in the oncedaily compared with the twice-daily routine, but this did not reach statistical significance.
James Parkinson in 1800 wrote in his essay The Hospital Pupil: 'Shrink not therefore in the least from your duty, point out the absolute propriety of complying with your directions in terms as strong as you can employ, and in no case submit to adopt a different line of conduct than that which science directs'. We have tried very hard to do that in this group of hypertensive patients, and yet one third of the time the goal was not achieved. Even now, with simple drug regimes, the problem of persuading asymptomatic patients to take drugs reliably remains a real challenge for the future.
